Autolus Therapeutics, which is developing cancer therapies based on CAR-T cell technology, announced terms for its IPO on Friday.
The London, United Kingdom-based company plans to raise $125 million by offering 7.8 million ADSs at a price range of $15 to $17. At the midpoint of the proposed range, Autolus Therapeutics would command a fully diluted market value of $620 million and an enterprise value of $372 million.
Autolus Therapeutics was founded in 2014 and booked $2 million in sales for the 12 months ended September 30, 2017. It plans to list on the Nasdaq under the symbol AUTL. Goldman Sachs and Jefferies are the joint bookrunners on the deal. It is expected to price during the week of June 18, 2018.
